Related references
Note: Only part of the references are listed.Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney et al.
EUROPEAN HEART JOURNAL (2022)
Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries
Vera Bittner et al.
JAMA CARDIOLOGY (2019)
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Konstantinos C. Koskinas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Ronen Arbel et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data
Maria Lindh et al.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2019)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Marc S. Sabatine et al.
CIRCULATION (2018)
Lipid Testing and Statin Dosing After Acute Myocardial Infarction
William T. Wang et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
Dennis T. Ko et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials
Aris Karatasakis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context
Peter P. Toth et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
Christopher P. Cannon et al.
JAMA CARDIOLOGY (2017)
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Insights From the Department of Veterans Affairs
Salim S. Virani et al.
CIRCULATION (2017)
Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands
Josephina G. Kuiper et al.
CLINICAL THERAPEUTICS (2017)
Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study
Sune Fallgaard Nielsen et al.
EUROPEAN HEART JOURNAL (2016)
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Todd J. Anderson et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Relationship between cardiovascular risk and lipid testing in one health care system: a retrospective cohort study
Robert J. Reid et al.
BMC HEALTH SERVICES RESEARCH (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the Canadian GRACE Experience)
Basem Elbarouni et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
Uchechukwu K. Sampson et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG) (vol 160, pg 1130, 2010)
Usman Javed et al.
AMERICAN HEART JOURNAL (2011)
Contemporary management of dyslipidemia in high-risk patients: Targets still not met
Andrew T. Yan et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Association between lipid testing and statin therapy in acute myocardial infarction patients
DT Ko et al.
AMERICAN HEART JOURNAL (2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
HD Aronow et al.
LANCET (2001)
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - The MIRACL study: A randomized controlled trial
GG Schwartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality
JB Muhlestein et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Share Paper
